Turn Therapeutics (TTRX) Registration filing summary

Company overview and business model

• Clinical-stage biotech developing topical, non-systemic GX-03 for atopic dermatitis (AD), hidradenitis suppurativa (HS) and onychomycosis; PHMB-based formula has prior FDA-cleared medical-device uses.

• Phase 2b AD trial targets 120–136 patients; topline results expected in Q1 2027. Phase 2a enrolled 50 completers and had no serious adverse events or treatment-related discontinuations.

• Business model pairs drug development with licensing and partner commercialization of medical-device products; a lean, outsourced operating model is intended to limit cash burn.

• Medline agreement provides a multi-year framework for co-development, supply and commercialization of PermaFusion-based products across Medline’s global professional and retail networks.

Use of proceeds and capital allocation

• No proceeds from selling-stockholder resales; up to $85.0 million gross may be raised through GEM share sales, with estimated net proceeds up to $84.95 million over ~36 months.

• GEM financing proceeds are intended for working capital and general corporate purposes; allocation is at management’s discretion.

• As of Nov. 6, 2026, 1,235,200 shares had been sold to GEM for ~$4.07 million gross, with ~$75.0 million remaining under the $85.0 million limit.

Risk factors and disclosures

• Resale registration covers shares equal to 82.96% of common stock outstanding as of Nov. 6, 2026; actual or anticipated sales could materially pressure the share price.

• GEM draw-down pricing is 90% of the average closing price over 15 trading days, subject to a $1.00 floor and a volume limit; future issuance may substantially dilute holders.

• GX-03’s clinical efficacy, safety, regulatory pathway and commercialization remain uncertain; further development and required studies depend on trial results, FDA engagement and available capital.

• The auditor’s report on FY2024–FY2025 financial statements includes an explanatory paragraph regarding ability to continue as a going concern.

• Patent validity and ownership disputes may recur; a prior derivation proceeding did not result in the requested inventorship finding, and potential claims could seek royalties, damages or restrictions.